Drug Profile
SEP 227018
Alternative Names: SEP-227018Latest Information Update: 21 May 2010
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Dainippon Sumitomo Pharma
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 21 May 2010 Discontinued - Phase-II for Insomnia in USA (unspecified route)
- 17 Feb 2010 Phase-II clinical trials in Insomnia in USA (unspecified route)